

# Using text message reminders and culturally-tailored telephone calls to promote participation in bowel cancer screening (TOPPS)

<b>Submission date</b> 15/09/2022	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 20/02/2023	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 08/10/2025	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Bowel cancer is a leading cause of cancer-related death in England. Several large studies have shown that screening can improve bowel cancer outcomes by detecting cases early. In light of this, NHS England initiated a national bowel cancer screening programme (BCSP) in 2006. Since then, uptake has been consistently low, falling from 54% in 2010 to 49% in 2015. Further, in London, participation in bowel cancer screening is particularly low in regions where there is high ethnic diversity.

However, previous research suggests that it is possible to improve screening uptake by using text message reminders and patient navigation (one-to-one support and guidance for patients throughout their decision-making regarding screening). This study aims to compare the effectiveness, and cost-effectiveness, of these two strategies to increase bowel cancer screening participation in six areas in London, where screening uptake is known to be low. This will provide policy-decision makers with the information needed to commission these services.

### Who can participate?

Men and women aged 60-74 years registered with a participating general practice located within the London Boroughs of Brent, Ealing, Lambeth, Lewisham, Redbridge and Barking and Dagenham, who have not returned a bowel cancer screening kit within 13 weeks of delivery

### What does the study involve?

Over a 4-week period, participants will be allocated (at random) to groups receiving either usual care, text message reminders at 13, 15, 17, 19 weeks of non-response, or a text message reminder at 13 weeks plus patient navigation at 15, 17, 19 weeks of non-response.

### What are the possible benefits and risks of participating?

The risks and burdens to participants are minimal. The NHS Bowel Cancer Screening invitation process will continue, unaffected by this study. Only those who do not participate within 13 weeks of invitation will be included in the study. These individuals will either receive no intervention (usual care), one or more text message reminders (depending on if/how soon they respond), or a call to discuss and rectify any barriers to attendance to support self-referral

(patient navigation).

There is potential that participants may feel that they are receiving too much information about bowel cancer screening, or are being coerced into participating in bowel cancer screening. However, the researchers will endeavour to ensure the interventions focus on enhancing informed choice and are delivered at suitable time points to not overwhelm individuals. This study benefits from a developmental phase, whereby people will help develop intervention content, and lay representatives will provide valuable input to the final designs. An advisory group and a steering group have also been established for this study and potential risks and burdens to participants will be addressed.

The main benefits of this study are that they may encourage participation in bowel cancer screening, which may help detect some bowel cancers at an earlier stage. The early detection of bowel cancer may, in turn, lead to improved cancer experience (e.g. less invasive treatment) and improved chances for survival.

Where is the study run from?

University College London (UK)

When is the study starting and how long is it expected to run for?

August 2021 to September 2025

Who is funding the study?

NHS England (UK)

Who is the main contact?

Dr Robert Kerrison, Robert.Kerrison.13@ucl.ac.uk

## Contact information

### Type(s)

Principal investigator

### Contact name

Dr Robert Kerrison

### ORCID ID

<https://orcid.org/0000-0002-8900-749X>

### Contact details

1-19 Torrington Place

London

United Kingdom

WC1E 7HB

+44 (0)20 7679 1722

Robert.Kerrison.13@ucl.ac.uk

## Additional identifiers

### Clinical Trials Information System (CTIS)

Nil known

## **Integrated Research Application System (IRAS)**

299034

## **ClinicalTrials.gov (NCT)**

Nil known

## **Protocol serial number**

150666, IRAS 299034

# **Study information**

## **Scientific Title**

Exploring the effectiveness and cost-effectiveness of text-message reminders and telephone patient navigation to improve the uptake of faecal immunochemical test screening among non-responders in London: a randomised controlled trial

## **Acronym**

TOPPS

## **Study objectives**

1. Bowel cancer screening non-responders who receive text message reminders 12 weeks after being sent a screening kit will be more likely to complete and return a test kit, compared with those who do not receive text message reminders (usual care).
2. Bowel cancer screening non-responders who receive text message reminders and telephone patient navigation 12 weeks after being sent a screening kit will be more likely to complete and return a test kit, compared with those who do not receive text message reminders or telephone patient navigation (usual care).
3. Bowel cancer screening non-responders who receive text message reminders and telephone patient navigation 12 weeks after being sent a screening kit will be more likely to complete and return a test kit, compared with those who receive text message reminders only.

## **Ethics approval required**

Ethics approval required

## **Ethics approval(s)**

approved 09/03/2023, Black Country Research Ethics Committee (The Old Chapel, Royal Standard Place, Nottingham, NG1 6FS, United Kingdom; +44 (0)207 104 8010; blackcountry.rec@hra.nhs.uk), ref: 22/WM/0212

## **Study design**

Randomized controlled trial

## **Primary study design**

Interventional

## **Study type(s)**

Screening

## **Health condition(s) or problem(s) studied**

Bowel cancer screening

## **Interventions**

Participants will be randomised using computerised, pseudo-random, number allocation (performed using the 'RAND' function within Excel). Individuals will be randomised in equal proportions (1:1:1) to receive either:

1. No intervention ('usual care only'),
2. A text-message reminder, 13 weeks after invitation, with additional text-message reminders at 15, 17 and 19 weeks, if there is no response ('usual care + text message reminder(s)'), or
3. A text-message reminder, 13 weeks after invitation, followed by PN calls at 15, 17 and 19 weeks, if there is no response ('usual care + a text message reminder + PN telephone call(s))

## **Intervention Type**

Behavioural

## **Primary outcome(s)**

Participation in screening, defined as returning a completed FIT kit, within 24 weeks of dispatch

## **Key secondary outcome(s)**

The proportion of participants who receive a positive bowel cancer screening test kit result, within 26 weeks of being sent their test kit

## **Completion date**

11/09/2025

## **Eligibility**

### **Key inclusion criteria**

1. Men and women aged 60-74 years
2. Have not returned a bowel cancer screening kit within 13 weeks of delivery
3. Registered with a participating general practice located within the London Boroughs of Brent, Ealing, Lambeth, Lewisham, Redbridge and Barking and Dagenham

### **Participant type(s)**

All

### **Healthy volunteers allowed**

No

### **Age group**

Mixed

### **Sex**

All

### **Total final enrolment**

3129

### **Key exclusion criteria**

Exclusions will be made according to 'Type-2 objector' status, which is defined as: "a request, expressed by a registered patient, logged with a GP Practice, to indicate that personal identifiable information relating to them should not be disseminated or published by NHS Digital.

**Date of first enrolment**

23/06/2025

**Date of final enrolment**

14/07/2025

## **Locations**

**Countries of recruitment**

United Kingdom

England

**Study participating centre**

**NHS North West London CCG**

15 Marylebone Road

London

United Kingdom

NW1 5JD

**Study participating centre**

**NHS South East London CCG**

160 Tooley Street

London

United Kingdom

SE1 2TZ

**Study participating centre**

**NHS North East London CCG**

UNEX Tower

5 Station Street

London

United Kingdom

E15 1DA

## **Sponsor information**

## Organisation

University College London

## ROR

<https://ror.org/02jx3x895>

## Funder(s)

### Funder type

Government

### Funder Name

NHS England

## Results and Publications

### Individual participant data (IPD) sharing plan

At the end of the study, an anonymised version of the study database will be made available on Open Science Framework. Eligible patients registered at a participating GP practice will be identified by NHS Digital. This list will be transferred securely to an encrypted cloud-based server (iPlato) for randomisation and intervention delivery. Following completion of the study period, this database will be transferred back to NHS digital for data on cancer screening participation (and outcome) to be extracted and anonymised, and relevant participant information to be attached. This will include 'sex', 'age', 'index of multiple deprivation quintile'. The anonymised dataset will then be transferred to UCL's Data Safe Haven for analysis. Consent will not be required at the participant level for research of this nature and will be given by GP participation.

### IPD sharing plan summary

Stored in publicly available repository

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Protocol article</a>		25/06/2024	25/06/2024	Yes	No
<a href="#">HRA research summary</a>			26/07/2023	No	No